Disease · MONDO_0024330

infectious otitis media

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. infectious otitis media. Diseases, record MONDO_0024330. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024330

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: infectious otitis media; Open Targets
Open Targets ID: MONDO_0024330; Open Targets
Other names: AOM, acute otitis Media, middle Ear infection; Open Targets
NCI Thesaurus: C84354; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 5 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AMOXICILLIN	CHEMBL1082	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BENZOCAINE	CHEMBL278172	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MOXIFLOXACIN	CHEMBL32	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OFLOXACIN	CHEMBL4	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CEFDINIR	CHEMBL927	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CLAVULANIC ACID	CHEMBL777	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
COLFOSCERIL PALMITATE	CHEMBL1200737	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01511107	Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance	Phase 2	520	2017-02-10	Acute Otitis Media	AMOXICILLIN	Its record names the disease	ClinicalTrials.gov
NCT02630992	Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media	Phase 3	112	2018-01-03	Acute Otitis Media	AMOXICILLIN	Its record names the disease	ClinicalTrials.gov
NCT03818815	A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months	Phase 2	103	2020-08-11	Acute Otitis Media	AMOXICILLIN, CLAVULANIC ACID, COLFOSCERIL PALMITATE	Its record names the disease	ClinicalTrials.gov
NCT00796224	Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media	Phase 2	38	2010-01-25	Acute Otitis Media	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00578474	A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes	Phase 3	911		Acute Otitis Media	OFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00643292	A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections	Phase 3	902		Acute Otitis Media	AMOXICILLIN, AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00579189	Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes	Phase 3	776		Acute Otitis Media	MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00645203	Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media	Phase 2/3	447		Acute Otitis Media	CEFDINIR	Its record names the disease	ClinicalTrials.gov
NCT03116737	Phase III Study Evaluating Topical Benzocaine for Treatment of Acute Otitis Media in Children	Phase 3	141		Pain, Acute Otitis Media	BENZOCAINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Amoxicillin-Clavulanate, 10 Days vs Amoxicillin-Clavulanate, 5 Days: serious adverse events	3 of 257	5 of 258	515	NCT01511107	Trial comparisons
Drug: OP0201 + Antibiotics vs Placebo Comparator: Placebo + Antibiotics: Number of Participants With Adverse Events	48 of 55	36 of 48	103	NCT03818815	Trial comparisons
Drug: OP0201 + Antibiotics vs Placebo Comparator: Placebo + Antibiotics: deaths from any cause	0 of 55	0 of 48	103	NCT03818815	Trial comparisons
Drug: OP0201 + Antibiotics vs Placebo Comparator: Placebo + Antibiotics: serious adverse events	0 of 55	1 of 48	103	NCT03818815	Trial comparisons
60 mg/kg Azithromycin ER vs 30 mg/kg Azithromycin IR: serious adverse events	0 of 19	0 of 19	38	NCT00796224	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42572144	DERIVED	1	PubMed
37171965	DERIVED	1	PubMed
34851411	DERIVED	1	PubMed
28438923	DERIVED	1	PubMed
28002709	DERIVED	1	PubMed
24911895	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024330

GET https://conductscience.org/api/diseases/v1/MONDO_0024330/drugs

API reference For AI assistants